FDA Approves New Cabozantinib Formulation for Cancer Treatment

The FDA has granted final approval to OMCAZIO (cabozantinib) capsules by Handa Oncology, converting a previous tentative authorization. This new formulation, indicated for advanced kidney, liver, and certain neuroendocrine tumors, offers patients increased flexibility as it can be taken with or without food. This expands treatment options for several cancer types.